169293-50-9 Usage
Description
Nebivolol hydrochloride, also known as NEBIVOLOL HCL, is a synthetic, selective β1-adrenergic receptor blocker. It is a white to off-white powder with chemical properties that make it a potent pharmaceutical agent. NEBIVOLOL HCL is known for its ability to selectively target β1-adrenergic receptors, which contributes to its effectiveness in treating cardiovascular conditions.
Uses
Used in Pharmaceutical Industry:
NEBIVOLOL HCL is used as an antihypertensive agent for the treatment of hypertension. Its selective action on β1-adrenergic receptors helps to lower blood pressure by reducing cardiac output and heart rate, while exhibiting minimal effects on β2-adrenergic receptors, which are responsible for bronchodilation and vasodilation. This selective action results in fewer side effects compared to non-selective β-blockers, making it a preferred choice for patients with hypertension.
In addition to its primary use as an antihypertensive, NEBIVOLOL HCL may also have potential applications in other cardiovascular conditions, such as heart failure and angina, due to its vasodilatory effects and its ability to improve the overall cardiovascular function. However, further research and clinical trials are necessary to establish its efficacy and safety in these additional applications.
Check Digit Verification of cas no
The CAS Registry Mumber 169293-50-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,9,2,9 and 3 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 169293-50:
(8*1)+(7*6)+(6*9)+(5*2)+(4*9)+(3*3)+(2*5)+(1*0)=169
169 % 10 = 9
So 169293-50-9 is a valid CAS Registry Number.
InChI:InChI=1/C22H25F2NO4.ClH/c23-15-3-7-19-13(9-15)1-5-21(28-19)17(26)11-25-12-18(27)22-6-2-14-10-16(24)4-8-20(14)29-22;/h3-4,7-10,17-18,21-22,25-27H,1-2,5-6,11-12H2;1H
169293-50-9Relevant articles and documents
PROCESS FOR THE SYNTHESIS OF INTERMEDIATES OF NEBIVOLOL
-
Page/Page column 38-39, (2017/08/20)
The present invention relates to a novel process for the synthesis of the intermediate compounds constituted by chromanyl haloketones of formula III and 6-fluoro-2-(oxiran-2-yl) chromans of formula I. The intermediates thus obtained can be used for the sy
A NOVEL PROCESS FOR PREPARATION OF NEBIVOLOL INTERMEDIATES
-
Page/Page column 9, (2008/06/13)
The present invention relates to a process for separation of desired diastereomeric pair from a mixture of diastereomeric pairs thereby obtaining nebivolol intermediates. Thus, the mixture of (+)-[1S*(R*)]-6-fluoro-3,4-dihydro-α-[[(phenylmethyl)amino]methyl]-2H-1-benzopyran-2-methanol, (+)-[1S*(S*)]-6-fluoro-3,4-dihydro-2-oxiranyl-2H-1-benzopyran and ethanol is heated to reflux temperature and stirred for 8 hours at the same temperature to obtain (+)-[2R*[1S*,5S*(S*)]]+[2R*[1S*,5R*(R*)]]-α,α'-[phenylmethyliminobis(methylene)]bis[6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol]. Then the reaction mass is cooled to 10oC, the pH is adjusted to 2 with HCl gas and stirred for 45 minutes at 25oC to 30oC. Then the separated solid is filtered and dried to give (+)-[2R*[1S*,5S*(S*)]]-α,α'-[phenylmethyliminobis(methylene)]bis[6-fluoro-3,4-dihydro-2H-1-benzopyran-2- methanol] hydrochloride salt, which can be converted into nebivolol.
